Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)

NCT02707328 is registered in ClinicalTrials.gov with The Cooper Health System as lead sponsor.

NCT NCT02707328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02707328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
Lead sponsor
The Cooper Health System
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2015
Completion date
November 10, 2017
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, pancreas adenocarcinoma, pancreas cancer, pancreatic adenocarcinoma, pancreatic cancer